Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis
- 21 October 2004
- journal article
- clinical trial
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 20 (12) , 2031-2041
Abstract
SUMMARYObjective: The FACT study (Fosamax Actonel Comparison Trial) was a 1-year head-to-head trial comparing the efficacy and tolerability of once weekly (OW) alendronate 70 mg and OW risedronate ...Keywords
This publication has 18 references indexed in Scilit:
- Biochemical markers of bone remodelingEndocrinology and Metabolism Clinics of North America, 2003
- Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled studyCurrent Medical Research and Opinion, 2003
- The Efficacy and Tolerability of Risedronate Once a week for the Treatment of Postmenopausal OsteoporosisCalcified Tissue International, 2002
- Importance of Precision in Bone Density MeasurementsJournal of Clinical Densitometry, 2001
- Epidemiology of OsteoporosisRheumatic Disease Clinics of North America, 2001
- Fracture Risk Reduction with Alendronate in Women with Osteoporosis: The Fracture Intervention TrialThe Journal of Clinical Endocrinology & Metabolism, 2000
- Antifracture Efficacy of Antiresorptive Agents Are Related to Changes in Bone DensityThe Journal of Clinical Endocrinology & Metabolism, 2000
- Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal OsteoporosisOsteoporosis International, 2000
- Effects of Risedronate Treatment on Vertebral and Nonvertebral Fractures in Women With Postmenopausal OsteoporosisA Randomized Controlled TrialJAMA, 1999
- Effect of Alendronate on Risk of Fracture in Women With Low Bone Density but Without Vertebral FracturesResults From the Fracture Intervention TrialJAMA, 1998